Insight beyond Phase 3: Does real-world evidence impact how we treat high-risk AML
High-risk AML defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC).
Chair: Prof Hartmut Döhner
This is a promotional symposium for healthcare professionals only.
Prescribing information and adverse event reporting details will be available during the sessions of the symposium
